Similarly, in the NOAH trial, patients with HER2‐positive breast cancer randomized to preoperative therapy achieved a significantly higher pCR rate than those who received chemotherapy alone (43% vs. 22%; P = .0007), and this was associated with improved 5‐year event‐free survival (58% vs. 43%; HR = 0.64; P = .016) 34, 35. The gene discussed is ERBB2; the disease is breast carcinoma.